Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702181 · ClinicalTrials.gov registry record · Phase 1
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 12
- Study locations
NCT01702181: Completed Phase 1 study of Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT01702181 is a Phase 1 study of Atopic Dermatitis that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 92 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01702181, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to investigate the pharmacokinetics and safety of OPA-15406 in adult subjects with atopic dermatitis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tacrolimus
- DRUG OPA-15406
Study Locations (12)
Texas
- - College Station
- - Dallas
- - San Antonio
Florida
- - Orange Park
- - Tampa
Alabama
- - Mobile
Arizona
- - Hot Springs
California
- - Irvine
Indiana
- - Carmel
New Jersey
- - Berlin
North Carolina
- - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT01702181 record still lists
NCT01702181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01702181 lists 12 locations in 9 states (Texas, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT01702181 about?
NCT01702181 is a clinical study titled "A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis". The purpose of this study is to investigate the pharmacokinetics and safety of OPA-15406 in adult subjects with atopic dermatitis
What is the current status of trial NCT01702181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2012-08. Estimated completion is 2013-12.
What conditions does trial NCT01702181 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT01702181?
The interventions under investigation include: Placebo (DRUG), Tacrolimus (DRUG), OPA-15406 (DRUG).
Who is sponsoring clinical trial NCT01702181?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01702181 being conducted?
This trial has 12 study locations across Alabama, Arizona, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01702181's enrollment target sits among peer trials
92 88th of 150 higher than 62 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia